Paul Kruszka, Director of the Division of Genetics; Genentech Professor of Pediatrics at University of Virginia School of Medicine, shared a post by GeneDx, adding:
“I’m ready for targeted genome newborn screen! No surprise GUARDIAN caught a lot of attention/citations after being published.”
“JAMA named the GUARDIAN Newborn Genomic Screening Study among of its most impactful research of the year. While this is a recognition we’re proud to be part of, what matters even more is why it was chosen.
The GUARDIAN study identified serious, treatable conditions in newborns that standard screening would have missed. For families, that means answers sooner. For clinicians, it means more time and clarity to act.
The findings reinforce the role genomics can play alongside traditional newborn screening and point toward a more proactive model of care.
And the work continues. GUARDIAN is on track to enroll 100,000 infants in the coming years, expanding the evidence base and access to insights that can change outcomes from day one.”